<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>FOLFOX plus Bevacizumab (BEV) is one of he current standard treatments for unresectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In Europe and the United States, XELOX is a regimen which replaced 5-FU/LV of FOLFOX with <z:chebi fb="0" ids="31348">capecitabine</z:chebi> (XEL), an oral <z:chebi fb="0" ids="50266">prodrug</z:chebi> of fluorouracil </plain></SENT>
<SENT sid="2" pm="."><plain>Benefits of XELOX and FOLFOX are reported to be same in Europe and United States </plain></SENT>
<SENT sid="3" pm="."><plain>XELOX + BEV is recommended as treatment option in various guidelines </plain></SENT>
<SENT sid="4" pm="."><plain>However, the safety and effectiveness data were from overseas and unconfirmed in Japan </plain></SENT>
<SENT sid="5" pm="."><plain>Therefore, we carried out a JO19380 study to evaluate the effectiveness and safety XELOX + BEV on Japanese patients in a domestic phase I/II clinical trial </plain></SENT>
<SENT sid="6" pm="."><plain>A total of 64 patients were registered in this study </plain></SENT>
<SENT sid="7" pm="."><plain>The response rate was 72%, the progression free survival was 11 months, and the median survival time was 27.4 months with XELOX + BEV </plain></SENT>
<SENT sid="8" pm="."><plain>The common grade 3/4 toxicities were sensory neurotoxicity (17%) and <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (16%) </plain></SENT>
<SENT sid="9" pm="."><plain>The effectiveness and safety equivalents of overseas reports were confirmed in Japanese patients </plain></SENT>
<SENT sid="10" pm="."><plain>They suggested that XELOX + BEV has the potential to become one of the standard treatments for unresectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in Japan </plain></SENT>
<SENT sid="11" pm="."><plain>In the trial, long-term disease control with XEL-BEV was reported in patients who discontinued <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> because of adverse events </plain></SENT>
<SENT sid="12" pm="."><plain>Continuous treatment with XEL + BEV after XELOX + BEV is considered to be significant first-line therapy for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> based on that report </plain></SENT>
</text></document>